COVID-19 | Discover the latest peer-reviewed research articles from the Eastern Mediterranean Region
COVID-19 | Discover the latest peer-reviewed research articles from the Eastern Mediterranean Region
COVID-19 | Discover the latest publications published by WHO Regional Office for the Eastern Mediterranean
COVID-19 | Discover the latest publications published by WHO Regional Office for the Eastern Mediterranean

Administration of metformin in type 2 diabetes mellitus patients with chronic kidney disease; facts and myths
Sepahi, Mohsen Akhavan
Lakkakula, Bhaskar V.K.S.
Kellner, Steven James
Valizadeh, Rohollah
Qom University of Medical Sciences, Clinical Research Development Center, Fatemi Pediatric Hospital, School of Medicine, Department of Pediatric Nephrology

J. Nephropathol. 2020; 9 (1): 1[e04]-6
JNP-Journal of Nephropathology
Journal Country: Islamic Republic of Iran
P-ISSN: 2251-8363
E-ISSN: 2251-8819
Type of Publication: Review
Category: Humans, Other Animals,
Type of Research: Clinical
Indexing Status : Archived
Broad Subjects: Diabetes,
Citation: Mohsen Akhavan Sepahi, Bhaskar V.K.S. Lakkakula, Steven James Kellner, Rohollah Valizadeh, Administration of metformin in type 2 diabetes mellitus patients with chronic kidney disease; facts and myths. J. Nephropathol. 2020; 9 (1): 1[e04]-6 . https://doi.org/10.15171/jnp.2020.04

There are few publications reporting adverse effects of metformin for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Although some of these reports have made big claims about the adverse effects of metformin in patients with renal failure, the majority of studies showed a superior safety profile for metformin compared with other antidiabetic medications in these patients. Further, metformin use is not contributing to an increased incidence of acute kidney injury (AKI). In conclusion, we suggest that a low dose of metformin is safe to use in patients with or without CKD. Multicenter randomized trials are required to further discover the benefits of the risk of metformin therapy in different stages of CKD and its effect on progression of CKD

  1. Tanner C, Wang G, Liu N, Andrikopoulos S, Zajac JD, Ekinci EI. Metformin: time to review its role and safety in chronic kidney disease. Med J Aust. 2019; 211:37-42. doi: 10.5694/mja2.50239.
  2. Hung SC, Chang YK, Liu JS, Kuo KL, Chen YH, Hsu CC, et al. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes Endocrinol. 2015;3:605–614. doi: 10.1016/S2213-8587(15)00123- 0.
  3. Lazarus B, Wu A, Shin JI, Sang Y, Alexander GC, Secora A, et al. Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study. JAMA Intern Med. 2018; 178:903– 910. doi: 10.1001/jamainternmed.2018.0292.
  4. De Broe ME, Kajbaf F, Lalau JD. Renoprotective effects of metformin. Nephron. 2018;138:261-274. doi: 10.1159/000481951.
  5. Eisenreich A, Leppert U. Update on the protective renal effects of metformin in diabetic nephropathy. Curr Med Chem. 2017;24:3397-412. doi: 10.2174/092986732466 6170404143102.
  6. Lee MC, Lee CH, Chang LY, Chang CH, Zhang JF, Lee MR, et al. Association of metformin use with end-stage renal disease in patients with type 2 diabetes mellitus: a nationwide cohort study under the pay-for-performance program. J Clin Pharmacol. 2019;59:1443- 52. doi:10.1002/jcph.1452.
  7. Carlson N, Hommel K, Olesen JB, Gerds TA, Soja AM, Vilsbøll T, et al. Metformin-associated risk of acute dialysis in patients with type 2 diabetes: a nationwide cohort study. Diabetes Obes Metab. 2016;18:1283-1287. doi: 10.1111/dom.
  8. Hsu WH, Hsiao PJ, Lin PC, Chen SC, Lee MY, Shin SJ. Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease. Oncotarget. 2018;9:5416–23.
  9. Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, et al. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2019; 21:1199-208. doi: 10.1111/dom.13642.
  10. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2015;38:140-9. doi: 10.2337/dc14-2441.
  11. Rodulfo JIA, Maini PA. Metformin in kidney diabetic disease: Current state. Rev Colom Nefrol. 2017;4:188- 199. doi:10.22265/acnef.4.2.255.
  12. Akhavan Sepahi M, Mehrabi S, Valizadeh R, Kellner SJ, Mirzazadeh A, Ebrahimi S. Nephroprotection and chemotherapy sensitivity impact of metformin during cisplatin therapy; an updated review. J Nephropathol. 2019;8:e45. doi: 10.15171/ jnp.2019.45.
  13. Neven E, Vervaet B, Brand K, Gottwald-Hostalek U, Opdebeeck B, De Maré A, et al. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder. Kidney Int. 2018; 94;102-113. doi: 10.1016/j.kint.2018.01.027.
  14. Dallak, M. Metformin pretreatment ameliorates diabetic nephropathy induced by a combination of high fat dietand streptozotocin in rats. Int J Morphol. 2018; 36:969- 974. doi:10.4067/S0717-95022018000300969.
  15. Ahmed Aziz KM. Unique glycemic and cardio-renal protective effects of metformin therapy among type-2 diabetic patients: a lesson from a five-year cross-sectional observational study of 1590 patients. J Endocrinol Diabetes Obes. 2014;2:1033. doi: 10.13070/rs.en.1.874.
  16. Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int. 2007;72(11):1367-73.
  17. Díaz MF, Valente RA, Mosquera VB, Abuward I, Martínez SP, Ardha N, et al. Metformin challenges in advanced chronic kidney disease: a promising therapeutic strategy. Jour Ren Med. 2017;1:1-12.
  18. Liu Z, Yu X, Tong C, Qi H. Renal dysfunction in a mouse model of GDM is prevented by metformin through MAPKs. Mol Med Rep. 2019;19:4491-9. doi: 10.3892/ mmr.2019.10060.
  19. Durham N, Crowley MJ, Diamantidis CJ, Williams Jr JW, McDuffie JR, Cameron B, et al. Metformin Use in Patients with Contraindications or Precautions. Washington (DC): Department of Veterans Affairs (US); 2016.
  20. Good CB, Pogach LM. Should Metformin be first-line therapy for patients with type 2 diabetes and chronic kidney disease? Informed patients should decide. JAMA Intern Med. 2018;178:911-2. doi: 10.1001/ jamainternmed.2018.0301.
  21. Cole NI, Swift PA, Suckling RJ, Andrews PA. Metformin in advanced chronic kidney disease: are current guidelines overly restrictive? Br J Diabetes. 2016;16:168-175.
  22. MacCallum L, Senior PA. Safe use of metformin in adults with type 2 diabetes and chronic kidney disease: lower dosages and sick-day education are essential. Can J Diabetes. 2019;43:76-80. doi: 10.1016/j. jcjd.2018.04.004.
  23. Richards S. Metformin and patients on dialysis. Aust Prescr. 2016;39:74-5.
  24. Chowdhury TA, Wright R, Yaqoob MM. Using metformin in the presence of renal disease: current guidelines are too restrictive, and many patients who could benefit are missing out. BMJ. 2015;349:h1758. doi: 10.1136/bmj. h1758.
  25. Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract. 2011;118:380-3. doi: 10.1159/000323739.
  26. Balogh Z, Mátyus J. Proposal for the administration of metformin in patients with chronic kidney disease. ORV Hetil. 2012;153:1527-35. doi: 10.1556/OH.2012.29448
  27. Christiansen CF, Ehrenstein V, Heide-Jørgensen U, Skovbo S, Nørrelund H, Sørensen HT, et al. Metformin initiation and renal impairment: a cohort study in Denmark and the UK. BMJ Open. 2015;5:e008531. doi: 10.1136/bmjopen-2015-008531.
  28. Dissanayake AM, Wheldon MC, Ahmed J, Hood CJ. Extending metformin use in diabetic kidney disease: a pharmacokinetic study in stage 4 diabetic nephropathy.Kidney Int Rep. 2017;2:705-712. doi: 10.1016/j. ekir.2017.03.005.
  29. Frid A, Sterner GN, Londahl M, Wiklander C, Cato A, Vinge E, et al. Novel assay of metforminlevels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care. 2010;33:1291- 3. doi: 10.2337/dc09-1284.
  30. Al-Hwiesh AK, Abdul-Rahman IS, El-Deen MA, Larbi E, Divino-Filho JC, Al-Mohanna FA, et al. Metformin in peritoneal dialysis: a pilot experience. Perit Dial Int. 2014; 34:368-75. doi: 10.3747/pdi.2013.00048.
  31. Heaf J. Metformin in chronic kidney disease: time for a rethink. Perit Dial Int. 2014;34:353-7. doi: 10.3747/ pdi.2013.00344.
  32. Duong JK, Roberts DM, Furlong TJ, Kumar SS, Greenfield JR, Kirkpatrick CM, et al. Metformin therapy in patients with chronic kidney disease. Diabetes Obes Metab. 2012;14:963-5.
  33. Abdelmoneim AS, Eurich DT, Light PE, Senior PA, Seubert JM, Makowsky MJ, et al. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. Diabetes Obes Metab. 2015;17:523- 32. doi: 10.1111/dom.12456.
  34. Gamble JM, Simpson SH, Eurich DT, Majumdar SR, Johnson JA. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab. 2010; 12:47-53. doi: 10.1111/j.1463-1326.2009.01125.x.
  35. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab. 2012;14:803-9. doi: 10.1111/j.1463-1326.2012.01604.x.
  36. Wheeler S, Moore K, Forsberg CW, Riley K, Floyd JS, Smith NL, et al. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia. 2013;56:1934- 43. doi: 10.1007/s00125-013-2958-1.
  37. Leyco T, Ryanputra D, Peh R, Ponce A, Khoo CM. Glycaemic control after metformin discontinuation in diabetic patients with a declining renal function. J Diabetes Res. 2017;2017:6. doi: 10.1155/2017/2769819.
  38. Ekstrom N, Schioler L, Svensson AM, Eeg-Olofsson K, Miao Jonasson J, Zethelius B, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open. 2012;2:e001076.
  39. Hung AM, Roumie CL, Greevy RA, Liu X, Grijalva CG, Murff HJ, et al. Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure and glycemic control. Pharmacoepidemiol Drug Saf. 2013; 22:623-31.
  40. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352:854-65.
  41. Wilkinson SV, Tomlinson LA, Iwagami M, Stirnadel- Farrant HA, Smeeth L, Douglas I. A systematic review comparing the evidence for kidney function outcomes between oral antidiabetic drugs for type 2 diabetes. Wellcome Open Res. 2018;3:74. doi: 10.12688/ wellcomeopenres.14660.1.
  42. Roumie CL, Min JY, D’Agostino McGowan L, Presley C, Grijalva CG, Hackstadt AJ, et al. Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: A cohort study. J Am Heart Assoc. 2017;6:e005379. doi: 10.1161/JAHA.116.005379.
  43. Hung AM, Roumie CL, Murff HJ, Grijalva CG, Liu X, Murff HJ, et al. Comparative effectiveness of second-line agents for the treatment of diabetes type 2 in preventing kidney function decline. Clin J Am Soc Nephrol. 2016;11:2177-85. doi: 10.2215/CJN.02630316.
  44. Ermini G, Tosetti C, Zocchi D, Mandreoli M, Caletti MT, Marchesini G, et al. Type 2 diabetes treatment and progression of chronic kidney disease in Italian family practice. J Endocrinol Invest. 2019;42:787-96. doi: 10.1007/s40618-018-0983-0.
  45. Hippisley-Cox J, Coupland C. Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care. BMJ. 2016;352:i1450.
  46. Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE. Risks of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;4:CD002967. doi: 10.1002/14651858.
  47. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Metformin, sulphonylureas, or other antidiabetes drugs and risk of lactic acidosis or hypoglycemia. Diabetes Care. 2008;31:2086-91. doi: 10.2337/dc08-1171.
  48. Bell S, Farran B, McGurnaghan S, McCrimmon RJ, Leese GP, Petrie JR, et al. Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study. BMC Nephrol. 2017;18:163. doi: 10.1186/s12882-017-0579-5.
Full Text English
Request full text